Latest News for PBYI
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan,…
Puma Biotechnology, Inc. (NASDAQ: PBYI - Get Free Report) shares passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $5.76 and traded as high as $6.23. Puma Biotechnology shares last traded at $6.13, with a volume of 182,822 shares traded. Analyst Ratings Changes Several analysts recently
PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.
Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.
Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PBYI.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.